Problems with drug-eluting coronary stents-the FDA perspective

Article Abstract:

An insight into the problems related to using Drug-eluting coronary stents like Cordis Cypher sirolimus eluting stent and Boston scientific Taxus Express paclitaxel eluting stent, which were approved, by the Food and Drug Administration (FDA) is highlighted. These drugs are associated with highly publicized adverse effects after FDA approved them for marketing, leading some questions to their safety.

Alliances, partnerships, Licensing/Sales Agreements, Licensing agreements, Company licensing agreement, United States. Food and Drug Administration, Ciphers

---

Drug-induced prolongation of the QT interval

Article Abstract:

The current knowledge about molecular and clinical predictors of drug-induced prolongation of the QT interval associated with polymorphism ventricular tachycardia, which can be fatal, is summarized. The ways in which new predictors of a drug's activity might be incorporated into drug development programs for a more general approach is discussed.

Analysis, Influence, Genetic polymorphisms, Queuing theory

---

Long-QT syndrome

Article Abstract:

The article discusses the long-QT syndrome that creates an increased risk of sudden death, usually due to ventricular fibrillation and recommends guidelines for dealing with it.

Care and treatment, Case studies, Patient outcomes, Diagnosis, Ventricular fibrillation, Long QT syndrome, Disease/Disorder overview

Similar abstracts:

• Abstracts: Prevention of coronary artery disease is a pediatric problem. Improving risk of coronary heart disease: can a picture make the difference?
• Abstracts: Accidental deaths drop. Resolution for safety in the new year. Time for employers to take the lead in safe driving effort
• Abstracts: Perspective on mitral-valve prolapse. Preventing coronary restenosis and complications. Hypertrophic obstructive cardiomyopathy
• Abstracts: Provocation of Coronary vasospastic angina using an Isoproterenol head-up Tilt Test. Prevention of Recurrent Deep Venous Thrombosis with Sulodexide: the Sanval registry

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.